A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Zosurabalpin following Intravenous Administration in Healthy Participants

2023-505411-20-00 Protocol BP44773 Human pharmacology (Phase I) - First administration to humans Ended

Start 20 Sep 2023 · End 28 Mar 2024 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol BP44773

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ended
Participants planned 30
Countries 1
Sites 1

There is no medical condition being investigated. This is a safety and pharmacokinetic study to be performed in healthy participants.

Key facts

Sponsor
F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Not possible to specify
Trial duration
20 Sep 2023 → 28 Mar 2024
Decision date (initial)
2023-09-12
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

There is no medical condition being investigated. This is a safety and pharmacokinetic study to be performed in healthy participants.

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

F. Hoffmann-La Roche AG

Sponsor organisation
F. Hoffmann-La Roche AG
Address
Grenzacherstrasse 124
City
Basel
Postcode
4058
Country
Switzerland

Scientific contact point

Organisation
F. Hoffmann-La Roche AG
Contact name
Trial Information System - TISL

Public contact point

Organisation
F. Hoffmann-La Roche AG
Contact name
Trial Information System - TISL

F. Hoffmann-La Roche AG

Sponsor organisation
F. Hoffmann-La Roche AG
Address
Grenzacherstrasse 124
City
Basel
Postcode
4058
Country
Switzerland

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ended 30 1
Rest of world 0

Investigational sites

Netherlands

1 site · Ended
Pharmaceutical Research Associates Group B.V.
Program Management, Van Swietenlaan 6, 9728 NZ, Groningen

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2023-09-20 2024-03-28 2023-09-20 2024-02-14

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-07-24 Netherlands Acceptable
2023-09-12
2023-09-12
2 SUBSTANTIAL MODIFICATION SM-2 2023-12-08 Netherlands Acceptable 2023-12-22
3 SUBSTANTIAL MODIFICATION SM-3 2024-02-27 Netherlands Acceptable
2024-03-28
2024-03-28